The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2018 | Avapritinib for advanced systemic mastocytosis: analysis of patient-reported outcomes from EXPLORER
Daniel DeAngelo, MD, PhD, of the Dana-Farber Cancer Institute, Boston, MA, speaking at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, discusses the analysis of the patient-reported outcomes data for avapritinib, a potent inhibitor of KIT D816V for advanced systemic mastocytosis. This interview took place at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.
